Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia, Schizo Affective Disorder
Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)
To characterize the real-life clinical use of AOM in a hospitalized patient population with schizophrenia, schizoaffective disorder or BP1 requiring LAI therapy and evaluate its short-term effectiveness associated with its…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
- Trial name
- INITIATE (NCT04907279)
- Testing
- Aripiprazole Once-Monthly (AOM)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Otsuka Canada Pharmaceutical Inc.
Schizophrenia
A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.
The purpose of this study is to determine the efficacy (effectiveness) and safety of paliperidone ER compared with placebo in the prevention of recurrence of symptoms of schizophrenia.
- Trial name
- NCT00086320
- Testing
- Paliperidone ER
- Volunteers
- 111 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.
- Trial name
- ASPIRE (NCT00705783)
- Testing
- Aripiprazole depot
- Where
- 110 sites in United States, Argentina and 10 more
- Volunteers
- 843 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects
This study aims to investigate the safety, tolerability and pharmacokinetic characteristics of KR23248 capsules in healthy subjects. This study will be conducted in China.
- Trial name
- NCT07585383
- Testing
- KR23248
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
Psychosis, Clinical High Risk for Psychosis
Using Mobile Technology to Enhance Early Psychosis Treatment Delivery
This project tests the feasibility of implementing a smartphone application - Ginger.io - in the UC Davis Early Psychosis Program, and investigates whether mobile health technology can improve treatment delivery and outcomes in…
- Trial name
- RWJFGinger (NCT03303456)
- Testing
- Mobile health application - Ginger.io
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Schizophrenia
Seroquel XR in Adults With Schizophrenia
The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally…
- Trial name
- NCT00852631
- Testing
- Quetiapine fumarate (Seroquel)
- Where
- 3 sites in Thailand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Schizophrenic Disorders, Cognitive Function
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
The purpose of this grant is to evaluate the efficacy of sodium butyrate as a novel treatment for cognitive deficits in schizophrenia (SZ).
- Trial name
- NCT02654405
- Testing
- Sodium Butyrate
- Where
- United States
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Metabolic Syndrome
The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain
Schizophrenia and bipolar disorders are major public health problems. The second generation anti-psychotic drugs have efficacy for both positive and negative symptoms and a favorable risk profile as far as movement disorders.
- Conditions
- Schizophrenia, Metabolic Syndrome, Vitamin D Deficiency
- Trial name
- NCT02281162
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Creighton University
Schizophrenia, Bipolar Disorder
ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health Registry
The purpose of this study is to find out how well new treatment plans are followed by outpatients with major mental illnesses (schizophrenia, bipolar disorder, depression, personality disorder) and to determine the relationship…
- Conditions
- Schizophrenia, Bipolar Disorder, Depression, Personality Disorder
- Trial name
- NCT00264069
- Testing
- antipsychotic, antidepressants
- Volunteers
- 2,622 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia
Effect of Nicotine Transdermal Patch on Cognitive Function and Glycolipid Metabolism in Non-smoking Schizophrenia
Schizophrenia is a group of severe mental disorders of unknown etiology, with significant abnormalities in mental activities such as cognition, thinking, emotion, and behavior, and lead to obvious occupational and social function…
- Trial name
- NCT05301660
- Testing
- Nicotine transdermal patch
- Volunteers
- 80 people
- Sponsor
- Sir Run Run Shaw Hospital
Bipolar Disorder, Schizophrenia
fMRI of Theory of Mind in Schizophrenia and Bipolar Disorder
Theory of mind (TOM), a main component of social cognition processes, refers to the capacity to infer one's own and other person's mental states.
- Trial name
- TOM-i (NCT02834182)
- Testing
- IRMf, Mini International Neuropsychiatric Interview, Positive And Negative Syndrom Scale
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Schizophrenia
A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia
The purpose of this study is to evaluate the long-term safety and tolerability and the maintenance of effectiveness of a slow, extended-release oral formulation of paliperidone administered once daily to patients diagnosed with…
- Trial name
- NCT00210769
- Testing
- paliperidone ER Oros
- Volunteers
- 203 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Tobacco Use Disorder
Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia
Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia.
- Trial name
- NCT00218231
- Testing
- 300 mg/day bupropion-sr, 0 mg/day bupropion-sr
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Schizophrenia
Assertive Community Treatment (ACT) in Schizophrenia Spectrum Disorders
The study examined the 12-month effectiveness of continuous therapeutic assertive community treatment (ACT) as part of integrated care (IC) compared to standard care (SC) in a catchment area comparison design in patients with…
- Trial name
- ACCESS (NCT01081418)
- Testing
- Assertive Community Treatment (ACT)
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Schizophrenia
A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, fixed-dosed phase II clinical study to evaluate the efficacy and safety of LY03020 in chinese acutely psychotic adult subjects with…
- Trial name
- NCT07396870
- Testing
- LY03020
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
A Long-Term Safety Study of Pomaglumetad Methionil in Schizophrenia
The purpose of this study is to evaluate the long-term safety of pomaglumetad methionil in participants with schizophrenia.
- Trial name
- NCT01487083
- Testing
- Pomaglumetad methionil
- Where
- 51 sites in United States, Austria and 9 more
- Volunteers
- 129 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
Therapeutic Effect of Cassia Seed in Obesity of Patients With Schizophrenia
Schizophrenia patients with anti-psychotics have decreased psychiatric symptoms, but have increased the generation of overweight or obesity.
- Trial name
- NCT04252131
- Testing
- cassia seed tablet
- Where
- Taiwan
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Calo Psychiatric Center
Mental Disorder
Do Consumer Providers Enhance Recovery?
Serious mental illness (SMI) is the second most costly disorder treated in the VHA, yet clinical outcomes for these patients in public sector settings are often poor due to a combination of low quality care and severe cognitive…
- Trial name
- PEER (NCT00781079)
- Testing
- Consumer Provider
- Where
- 7 sites in United States
- Volunteers
- 285 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorders
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
This study involves people with schizophrenia or schizoaffective disorder, who are currently taking antipsychotic medications. Some antipsychotic medications may cause an increase in cholesterol levels, which may lead to…
- Conditions
- Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
- Trial name
- NCT01082588
- Testing
- Pravastatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Device Adherence
Effectiveness of a Digital Platform in Engagement and Prognosis of Patients in an Early Intervention Pychosis Programme
This is a randomised, prospective, controlled trial in which one group (experimental group; GE) receives access to the PIPPEP (Intervention Programme for Early Psychosis) platform in addition to the treatment as usual (TAU) in…
- Trial name
- NCT06556251
- Testing
- PIPPEP App
- Where
- Spain
- Volunteers
- 128 people
- Sponsor
- Fundació Sant Joan de Déu
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.